// App-Quantinova.ai

TPS5085 : The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer.

Researchers

Presenter

  • Andrew J. Armstrong

Principal Investigators

  • Michael S. Gordon

  • Melissa Andrea Reimers

  • Alex Sedkov

  • Kate Lipford

  • Juliana Snavely-Merhaut

  • Sonia Kumar

  • Sylvie Mireille Guichard

  • Neal Shore

Medical Centers

  • Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC

  • HonorHealth Research Institute/TGen, Scottsdale, AZ

  • Division of Oncology, Washington University School of Medicine, St. Louis, MO

  • FORMA Therapeutics, Inc., Watertown, MA

  • Carolina Urologic Research Center, Myrtle Beach, SC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

  • CREB-binding protein

  • E1A Binding Protein P300

Drug/Treatment

  • Radium-223 Dichloride

  • Androgen Tear

  • taxane

Outcome

  • N/A

Study Design

  • Cohort

  • First-In-Human

Phase

  • I

Study Id's

  • NCT04575766

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved